Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker.
暂无分享,去创建一个
Y. Devaux | D. Wagner | L. Hoffmann | J. Renaut | S. Planchon | T. Bohn | B. Haas | G. Gilson | T. Serchi | Jenny Renaut | Daniel R. Wagner | Lucien Hoffmann | Benjamin Haas | Georges Gilson | Torsten Bohn
[1] A. Khera,et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.
[2] J. Eyk. Overview: the maturing of proteomics in cardiovascular research. , 2011 .
[3] Jennifer E Van Eyk,et al. Overview: The Maturing of Proteomics in Cardiovascular Research , 2011, Circulation research.
[4] Francisco Azuaje,et al. Transcriptional networks characterize ventricular dysfunction after myocardial infarction: A proof-of-concept investigation , 2010, J. Biomed. Informatics.
[5] Francisco Azuaje,et al. Integrated protein network and microarray analysis to identify potential biomarkers after myocardial infarction , 2010, Functional & Integrative Genomics.
[6] Francisco Azuaje,et al. Integrative Pathway-Centric Modeling of Ventricular Dysfunction after Myocardial Infarction , 2010, PloS one.
[7] Francisco Azuaje,et al. Coordinated modular functionality and prognostic potential of a heart failure biomarker-driven interaction network , 2010, BMC Systems Biology.
[8] L. Hoffmann,et al. Effects of the endocrine disruptors atrazine and PCB 153 on the protein expression of MCF-7 human cells. , 2009, Journal of proteome research.
[9] A. Roguin,et al. Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice , 2009 .
[10] David Tepper,et al. Declining In‐Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction , 2009 .
[11] I. Holme,et al. Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS) , 2009, Annals of medicine.
[12] Melanie Y. White,et al. The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery* , 2008, Molecular & Cellular Proteomics.
[13] I. Quaye. Haptoglobin, inflammation and disease. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[14] R. Ferrell,et al. Haptoglobin Genotype , 2008, Diabetes.
[15] A. Rigby,et al. The timing of development and subsequent clinical course of heart failure after a myocardial infarction. , 2008, European heart journal.
[16] F. Veglia,et al. Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage , 2008, European journal of heart failure.
[17] J. Renaut,et al. Quantitative proteomic analysis of short photoperiod and low-temperature responses in bark tissues of peach (Prunus persica L. Batsch) , 2008, Tree Genetics & Genomes.
[18] Francis G Spinale,et al. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.
[19] Leong L Ng,et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. , 2007, European heart journal.
[20] Francis G Spinale,et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. , 2006, Journal of cardiac failure.
[21] I. Quaye,et al. Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana. , 2006, Journal of atherosclerosis and thrombosis.
[22] D. Wagner,et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. , 2006, Journal of cardiac failure.
[23] A. Alayash. Redox biology of blood. , 2004, Antioxidants & redox signaling.
[24] S. Mao,et al. Purification of human haptoglobin 1-1, 2-1, and 2-2 using monoclonal antibody affinity chromatography. , 2004, Protein expression and purification.
[25] A. Alayash. Oxygen therapeutics: can we tame haemoglobin? , 2004, Nature Reviews Drug Discovery.
[26] Deborah Pinchev,et al. Mining biomarkers in human sera using proteomic tools , 2004, Proteomics.
[27] A. Levy. Genetics of diabetic cardiovascular disease: identification of a major susceptibility gene , 2003, Acta Diabetologica.
[28] Anderson Nl,et al. Therapeutic potential of the plasma proteome. , 2003 .
[29] N Leigh Anderson,et al. Therapeutic potential of the plasma proteome. , 2003, Current opinion in molecular therapeutics.
[30] A. Kastrati,et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. , 2002, Clinical chemistry.
[31] P. Kemmeren,et al. Acute‐phase protein haptoglobin is a cell migration factor involved in arterial restructuring , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] S. Moestrup,et al. Identification of the haemoglobin scavenger receptor , 2001, Nature.
[33] D. Duprez,et al. Haptoglobin polymorphism and peripheral arterial occlusive disease. , 1997, Atherosclerosis.
[34] O. Smithies,et al. Genetic Control of some Serum Proteins in Normal Humans , 1955, Nature.